<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A1825</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 1825 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  HERB CONAWAY, JR.</p>

<p class=bpuSponsor>District 7 (Burlington)</p>

<p class=bpuSponsor>Assemblyman  ANTHONY S. VERRELLI</p>

<p class=bpuSponsor>District 15 (Hunterdon and Mercer)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Assemblywomen Murphy, Swain, Assemblyman Tully,
Assemblywoman Speight, Assemblymen Danielsen, Karabinchak, Assemblywomen
Quijano, Lampitt, Lopez, N.Munoz, Tucker, Reynolds-Jackson, Dunn, Assemblymen
Stanley, Sauickie, Clifton, Assemblywomen Haider, Swift, Assemblyman DeAngelo,
Assemblywoman Carter, Assemblymen Bergen, Guardian and Azzariti Jr.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Establishes certain guidelines for health insurance
carriers concerning step therapy protocols. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> </span>concerning health insurance and supplementing
Title 26 of the Revised Statutes.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    The Legislature finds
and declares that:</p>

<p class=MsoNormal style='line-height:150%'>     a.     Health insurance plans
are increasing the use of step therapy protocols that require patients to try
one or more prescription drugs before coverage is provided for a drug selected
by the patients health care provider.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Step therapy protocols,
if based on well-developed scientific standards and administered in a flexible
manner that takes into account the individual needs of patients, can play an
important role in controlling health care costs.</p>

<p class=MsoNormal style='line-height:150%'>     c.     In some cases,
requiring a patient to follow a step therapy protocol may have adverse and even
dangerous consequences for the patient who may either not realize a benefit
from taking a prescription drug or may suffer harm from taking an inappropriate
drug.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Without uniform policies
in the State for step therapy protocols, all patients may not receive the
equivalent or most appropriate treatment. </p>

<p class=MsoNormal style='line-height:150%'>     e.     It is imperative that
step therapy protocols in the State preserve the heath care providers right to
make treatment decisions in the best interest of the patient.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The Legislature
declares, therefore, that it is a matter of public interest that health insurance
carriers be required to base step therapy protocols on appropriate clinical
practice guidelines or published peer-reviewed data developed by independent
experts with knowledge of the condition or conditions under consideration; that
patients be exempt from step therapy protocols when those protocols are
inappropriate or otherwise not in the best interest of the patients; and that
patients have access to a fair, transparent and independent process for
requesting an exception to a step therapy protocol when the patients physician
deems appropriate.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    As used in this act:</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Carrier&quot; means an
insurance company, health service corporation, hospital service corporation,
medical service corporation, or health maintenance organization authorized to
issue health benefits plans in this State.</p>

<p class=MsoNormal style='line-height:150%'>     Clinical practice guidelines
means a systematically developed statement to assist decision making by health
care providers and patient decisions about appropriate healthcare for specific
clinical circumstances and conditions.</p>

<p class=MsoNormal style='line-height:150%'>     Clinical review criteria
means the written screening procedures, decision abstracts, clinical protocols
and practice guidelines used by a carrier or utilization review organization to
determine the medical necessity and appropriateness of health care services. </p>

<p class=MsoNormal style='line-height:150%'>     Commissioner means the
Commissioner of Banking and Insurance.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Covered person&quot;
means a person on whose behalf a carrier offering the plan is obligated to pay
benefits or provide services pursuant to the health benefits plan.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Health benefits
plan&quot; means a benefits plan which pays or provides hospital and medical
expense benefits for covered services, and is delivered or issued for delivery
in this State by or through a carrier.  Health benefits plan includes, but is
not limited to, Medicare supplement coverage and risk contracts to the extent
not otherwise prohibited by federal law.  For the purposes of this act, health
benefits plan shall not include the following plans, policies, or contracts: 
accident only, credit, disability, long-term care, CHAMPUS supplement coverage,
coverage arising out of a workers' compensation or similar law, automobile
medical payment insurance, personal injury protection insurance issued pursuant
to P.L.1972, c.70 (C.39:6A-1 et seq.), or hospital confinement indemnity
coverage.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Health care
provider&quot; means an individual or entity which, acting within the scope of
its licensure or certification, provides a covered service defined by the
health benefits plan.  Health care provider includes, but is not limited to, a
physician and other health care professionals licensed pursuant to Title 45 of
the Revised Statutes, and a hospital and other health care facilities licensed
pursuant to Title 26 of the Revised Statutes.</p>

<p class=MsoNormal style='line-height:150%'>     Medically necessary means
health services and supplies that, under the applicable standard of care, are
appropriate:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   to improve or preserve
health, life, or function;  </p>

<p class=MsoNormal style='line-height:150%'>     (2)   to slow the
deterioration of health, life, or function; or </p>

<p class=MsoNormal style='line-height:150%'>     (3)   for the early screening,
prevention, evaluation, diagnosis or treatment of a disease, condition, illness
or injury.</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy exception means
the overriding of a step therapy protocol in favor of immediate coverage of the
health care providers selected prescription drug. </p>

<p class=MsoNormal style='line-height:150%'>     Step therapy protocol means
a protocol, policy, or program that establishes the specific sequence in which
prescription drugs for a specified medical condition, and medically appropriate
for a particular patient, are required to be administered in order to be
covered by a health benefits plan. </p>

<p class=MsoNormal style='line-height:150%'>     Utilization review
organization means an entity that conducts utilization review, other than a
carrier performing utilization review for its own health benefit plans.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    a.  Clinical review
criteria used to establish a step therapy protocol shall be based on clinical
practice guidelines that: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   recommend that the
prescription drugs be taken in the specific sequence required by the step
therapy protocol;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   are developed and
endorsed by a multidisciplinary panel of experts that manages conflicts of
interest among the members of the writing and review groups by:</p>

<p class=MsoNormal style='line-height:150%'>     (a)   requiring members to
disclose any potential conflict of interests with entities, including carriers
and pharmaceutical manufacturers, and recuse themselves from voting if they
have a conflict of interest; </p>

<p class=MsoNormal style='line-height:150%'>     (b)   using a methodologist to
work with writing groups to provide objectivity in data analysis and ranking of
evidence through the preparation of evidence tables and facilitating consensus;
and</p>

<p class=MsoNormal style='line-height:150%'>     (c)   offering opportunities
for public review and comments; and</p>

<p class=MsoNormal style='line-height:150%'>     (3)   are based on high
quality studies, research, and medical practice;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   are created by an
explicit and transparent process that:</p>

<p class=MsoNormal style='line-height:150%'>     (a)   minimizes biases and
conflicts of interest;</p>

<p class=MsoNormal style='line-height:150%'>     (b)   explains the
relationship between treatment options and outcomes;</p>

<p class=MsoNormal style='line-height:150%'>     (c)   rates the quality of the
evidence supporting recommendations; and</p>

<p class=MsoNormal style='line-height:150%'>     (d)   considers relevant
patient subgroups and preferences; and</p>

<p class=MsoNormal style='line-height:150%'>     (5)   are continually updated
through a review of new evidence, research and newly developed treatments.</p>

<p class=MsoNormal style='line-height:150%'>      b.   In the absence of
clinical guidelines that meet the requirements in subsection a. of this
section, peer-reviewed publications may be substituted. </p>

<p class=MsoNormal style='line-height:150%'>      c.    When establishing a
step therapy protocol, a utilization review agent shall also consider the needs
of atypical patient populations and diagnoses when establishing clinical review
criteria.</p>

<p class=MsoNormal style='line-height:150%'>      d.   A carrier shall:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   upon written request,
provide specific written clinical review criteria relating to a particular
condition or disease, including clinical review criteria relating to a step
therapy protocol exception determination; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   make available the
clinical review criteria and other clinical information on its internet website
and to a health care professional on behalf of an insured person upon written
request.</p>

<p class=MsoNormal style='line-height:150%'>      e.    This section shall not
be construed to require carriers or the State to establish a new entity to
develop clinical review criteria used for step therapy protocols.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    Notwithstanding the
provisions of any law, rule, or regulation to the contrary:</p>

<p class=MsoNormal style='line-height:150%'>      a.    When coverage of a
prescription drug for the treatment of any medical condition is restricted for
use by a carrier or utilization review organization pursuant to a step therapy
protocol, the carrier or utilization review organization shall provide the
covered person and prescribing practitioner a clear, readily accessible, and
convenient process to request a step therapy exception. A carrier or
utilization review organization may use its existing medical exceptions process
to satisfy this requirement. An explanation of the process shall be made
available on the carrier or utilization review organizations website.  A
carrier or utilization review organization shall disclose all rules and
criteria related to the step therapy protocol upon request to all prescribing
practitioners, including the specific information and documentation required to
be submitted by a prescribing practitioner or patient for an exception request
to be complete.</p>

<p class=MsoNormal style='line-height:150%'>      b.   A step therapy exception
shall be granted if: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   the required
prescription drug is contraindicated or is likely to cause an adverse reaction
or physical or mental harm to the patient;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   the required
prescription drug is expected to be ineffective based on the known clinical characteristics
of the patient and the known characteristics of the prescription drug regimen;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   the patient has tried
the required prescription drug or another prescription drug in the same
pharmacologic class or with the same mechanism of action and the prescription
drug was discontinued due to lack of efficacy or effectiveness, diminished
effect, or an adverse event; </p>

<p class=MsoNormal style='line-height:150%'>     (4)   the required
prescription drug is not in the best interest of the patient, based on medical
necessity; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   the patient is stable on
a prescription drug selected by their health care provider for the medical
condition under consideration. </p>

<p class=MsoNormal style='line-height:150%'>      c.    When a step therapy
exception is granted, the carrier or utilization review organization shall
authorize coverage for the prescription drug prescribed by the patients
treating health care provider.</p>

<p class=MsoNormal style='line-height:150%'>      d.   Any step therapy
exception shall be eligible for appeal by a covered person.  The carrier or
utilization review organization shall grant or deny a step therapy exception
request or an appeal of a step therapy exception request within 72 hours of
receipt of the request or appeal. In cases where exigent circumstances exist,
the carrier or utilization review organization shall respond within 24 hours of
receipt.  If a request for a step therapy exception is incomplete or if
additional clinically relevant information is required, the carrier or
utilization review organization shall notify the prescribing practitioner
within 72 hours of submission, or 24 hours in exigent circumstances, what
additional or clinically relevant information is required in order to approve
or deny the step therapy exception request or appeal pursuant to the criteria
disclosed pursuant to subsection a. of this section.  Once the requested
information is submitted, the applicable time period to grant or deny a step
therapy exception request or appeal shall apply.  If a response by a carrier or
utilization review organization is not received within the time allotted, the
exception or appeal shall be deemed granted.  In the event of a denial, the
carrier or utilization review organization shall inform the patient of the
appeal process.</p>

<p class=MsoNormal style='line-height:150%'>      e.    Any step therapy
exception pursuant to this section shall be eligible for appeal by a covered
person.</p>

<p class=MsoNormal style='line-height:150%'>      f.    This section shall not
be construed to prevent:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   a carrier or utilization
review organization from requiring a patient to try an AB-rated generic
equivalent or interchangeable biological product prior to providing coverage
for the equivalent branded prescription drug;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   a carrier or utilization
review organization from requiring a pharmacist to effect substitutions of
prescription drugs consistent with the laws of this State; or</p>

<p class=MsoNormal style='line-height:150%'>     (3)   a health care provider
from prescribing a prescription drug that is determined to be medically appropriate.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>      5.   Annually, a carrier or
utilization review organization shall report to the commissioner, in a format
prescribed by the commissioner: </p>

<p class=MsoNormal style='line-height:150%'>      a.    the number of step
therapy exception requests received, by reason for the exception;</p>

<p class=MsoNormal style='line-height:150%'>      b.   the type of health care
providers or the medical specialties of the health care providers submitting
step therapy exception requests; </p>

<p class=MsoNormal style='line-height:150%'>      c.    the number of step
therapy exception requests that were denied, by reason for the exception, and
the reasons for the denials; </p>

<p class=MsoNormal style='line-height:150%'>      d.   the number of step
therapy exception requests that were approved, by reason for the exception; </p>

<p class=MsoNormal style='line-height:150%'>      e.    the number of step
therapy exception requests that were initially denied and then appealed, by
reason for the exception;</p>

<p class=MsoNormal style='line-height:150%'>      f.    the number of step
therapy exception that were initially denied and then subsequently reversed by
internal appeals or external reviews, by reason for the exception; and </p>

<p class=MsoNormal style='line-height:150%'>      g.   the medical conditions
for which patients are granted exceptions due to the likelihood that switching
from the prescription drug will likely cause an adverse reaction by or physical
or mental harm to the insured.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>      6.   The commissioner shall
adopt, pursuant to the Administrative Procedure Act P.L.1968, c.410
(C.52:14B-1&nbsp;et&nbsp;seq.),&nbsp;rules and regulations to effectuate the
purposes of this&nbsp;act.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    This act shall take
effect on the 60th day after enactment and apply to all contracts and policies
delivered, issued, executed, or renewed on or after January 1, 2021.<br
clear=all style='page-break-before:always'>
</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span style='line-height:150%;
letter-spacing:0pt'>This bill requires health insurance carriers and
utilization review organizations to meet certain guidelines in the
administration and review of step therapy protocols.  The bill defines step
therapy protocol as a protocol, policy, or program that establishes the specific
sequence in which prescription drugs for a specified medical condition, and
medically appropriate for a particular patient, are covered by a health
benefits plan.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      The bill provides that clinical review criteria used
to establish a step therapy protocol is to be based on clinical practice
guidelines that:</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (1)   recommend that the prescription drugs be taken
in the specific sequence required by the step therapy protocol;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (2)   are developed and endorsed by a
multidisciplinary panel of experts that manages conflicts of interest among the
members of the writing and review groups by following certain procedures
outlined in the bill;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (3)   are based on high quality studies, research,
and medical practice;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (4)   are created by an explicit and transparent
process that minimizes biases and conflicts of interest, explains the
relationship between treatment options and outcomes, rates the quality of the
evidence supporting recommendations, and considers relevant patient subgroups
and preferences; and</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (5)   are continually updated through a review of new
evidence, research and newly developed treatments.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      In addition, the bill provides guidelines for the
review of step therapy exceptions.  Under the bill, step therapy exception
means the overriding of a step therapy protocol in favor of immediate coverage
of the health care providers selected prescription drug. </span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      The bill provides that when coverage of a
prescription drug for the treatment of any medical condition is restricted for
use by a carrier or utilization review organization through the use of a step
therapy protocol, the carrier or utilization review organization is to provide
the covered person and prescribing practitioner a clear, readily accessible,
and convenient process to request a step therapy exception. Under the bill, a
carrier or utilization review organization may use its existing medical
exceptions process to satisfy this requirement.  An explanation of the process
is to be made available on the carrier or utilization review organizations
website.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      A step therapy exception is to be granted if: </span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (1)   the required prescription drug is contraindicated
or is likely to cause an adverse reaction or physical or mental harm to the
patient;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (2)   the required prescription drug is expected to
be ineffective based on the known clinical characteristics of the patient and
the known characteristics of the prescription drug regimen;</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (3)   the patient has tried the required prescription
drug while under their current or a previous health insurance or health benefit
plan, or another prescription drug in the same pharmacologic class or with the
same mechanism of action and the prescription drug was discontinued due to lack
of efficacy or effectiveness, diminished effect, or an adverse event; </span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (4)   the required prescription drug is not in the
best interest of the patient, based on medical necessity; or</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      (5)   the patient is stable on a prescription drug
selected by their health care provider for the medical condition under
consideration while on a current or previous health insurance or health benefit
plan. </span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      Under the bill, when a step therapy exception is granted,
the carrier or utilization review organization is to authorize coverage for the
prescription drug prescribed by the patients treating health care provider.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      The bill provides that any step therapy exception is
to be eligible for appeal by a covered person.  The carrier or utilization
review organization is to grant or deny a step therapy exception request or an
appeal of a step therapy exception request within 72 hours of receipt of the
request or appeal.  In cases where exigent circumstances exist, the carrier or
utilization review organization is to respond within 24 hours of receipts. If a
response by a carrier or utilization review organization is not received within
the time allotted, the exception or appeal is to be deemed granted. </span></p>

<p class=MsoNormal style='line-height:150%'><span style='line-height:150%;
letter-spacing:0pt'>      The bill also provides that a carrier or utilization
review organization is to report to the Commissioner of Banking and Insurance
certain information concerning the number and nature of step therapy exceptions
requested, appealed, denied, and granted.</span></p>

</div>

</body>

</html>
